Update on phase III readout for bempeg/opdivo combo for metastatic #melanoma, with a hazard ratio of 1.09.

As expensive as brand-name drugs are, the patent expiration of the blockbuster #Humira has opened a floodgate of biosimilars, several primed to make an entry to market within the next few years.

Updates on data regarding nirsevimab

Basics of the drug pricing process, with a simple explanation of three important transition points: 1) manufacturer to wholesaler, 2) wholesaler to pharmacy, and 3) pharmacy to patient.

Great take on challenges of home health care

Nice commentary on implications of 'ERBB-2 low' breast cancer.

Study showing the inaccuracy of distinguishing 0 from 1+ with current #ERBB2 assays for T-DxD, the issue being that clinical trials and labs use an assay designed for high ERBB2.

Manufacturing techniques matter.

Cohort study finding that for high-risk prostate cancer patients receiving external beam radiation (EBRT) or EBRT with brachytherapy should be on ADT respectively for >18 months and 18 months (or less).

Good review of precision oncology, with current uses and limitations

Cerebral Health (parent company is Facebook, no surprise), a $300M+ startup connecting pts to therapists, pulled its dozens of ads on social media that associate impulsive eating with ADHD. I'm all for fighting obesity, but not w/ ineffective tactics.

While no drug has been approved on the basis of formal comparison to an external control arm in oncology, the paper summaries previous uses of ECAs, such as: natural history of disease in NF1; and placebo arm of a previous trial in paediatric population (4/4)

RT @haithamahmedmd: Mark Cuban launched an online pharmacy providing cancer, cardiac, GI, rheum drugs at a steep discount. Leukemia drug Im…

To differentiate PMM from metastatic #melanoma, 1) rule out cutaneous, regressed or visceral melanoma, 2) look for the recurrence pattern that can reflect primary origin. Can identify bladder melanoma with stains for S-100, HMB45, Melan-A. (3/3)